Hemogenyx Pharmaceuticals (LON:HEMO) Shares Down 6.4% – Time to Sell?

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares dropped 6.4% on Wednesday . The stock traded as low as GBX 0.95 ($0.01) and last traded at GBX 0.96 ($0.01). Approximately 6,211,438 shares traded hands during mid-day trading, a decline of 38% from the average daily volume of 10,021,008 shares. The stock had previously closed at GBX 1.03 ($0.01).

Hemogenyx Pharmaceuticals Stock Up 9.8 %

The firm has a market capitalization of £15.75 million, a P/E ratio of -114.00 and a beta of 3.14. The company has a debt-to-equity ratio of 92.09, a quick ratio of 6.72 and a current ratio of 4.38. The stock has a 50 day moving average of GBX 1.34 and a 200-day moving average of GBX 1.36.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.